HC Wainwright reiterated their buy rating on shares of HTG Molecular Diagnostics (NASDAQ:HTGM) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. HC Wainwright currently has a $2.00 price objective on the medical research company’s stock.
Other equities research analysts have also issued research reports about the company. ValuEngine upgraded HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reiterated an overweight rating on shares of HTG Molecular Diagnostics in a research note on Friday, October 18th. Craig Hallum set a $3.00 price objective on HTG Molecular Diagnostics and gave the company a buy rating in a research note on Friday, September 27th. Finally, Canaccord Genuity set a $1.50 price objective on HTG Molecular Diagnostics and gave the company a buy rating in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics has an average rating of Buy and an average target price of $3.13.
Shares of HTGM stock traded down $0.03 during trading hours on Tuesday, reaching $0.63. The company had a trading volume of 23,835 shares, compared to its average volume of 374,212. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.07 and a current ratio of 5.21. HTG Molecular Diagnostics has a twelve month low of $0.56 and a twelve month high of $3.24. The company has a market capitalization of $35.35 million, a P/E ratio of -1.09 and a beta of 1.56. The stock’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.90.
Several institutional investors and hedge funds have recently modified their holdings of HTGM. BlackRock Inc. grew its position in shares of HTG Molecular Diagnostics by 504.3% in the 2nd quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock worth $673,000 after acquiring an additional 338,681 shares in the last quarter. Vanguard Group Inc. raised its stake in HTG Molecular Diagnostics by 20.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after acquiring an additional 242,497 shares in the last quarter. Citadel Advisors LLC raised its stake in HTG Molecular Diagnostics by 153.9% during the 2nd quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 23,351 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its stake in HTG Molecular Diagnostics by 297.1% during the 3rd quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research company’s stock valued at $1,564,000 after acquiring an additional 1,760,533 shares in the last quarter. Institutional investors own 38.94% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Recommended Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.